Loading...
NPI 1851726731 · Teterboro, NJ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Infinity Diagnostics Laboratory, Inc is a clinical medical laboratory provider located in Teterboro, New Jersey. This profile covers 17 Medicare and 76 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Infinity Diagnostics Laboratory, Inc |
| Address | 370 North St |
| City | Teterboro |
| State | NJ |
| ZIP | 07608 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 10, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $138M |
| Medicare | $615.7K |
This provider’s payer mix is overwhelmingly weighted to Medicaid: lifetime Medicaid revenue is $138M compared with total Medicare revenue of $615.7K, indicating Medicaid accounts for the vast majority of its billing volume and economic scale. While Medicare activity exists, it is small in absolute dollars relative to Medicaid and the entity is effectively Medicaid‑driven at the enterprise level.
Both Medicare and Medicaid revenues are extremely concentrated in SARS‑CoV‑2 diagnostic activity. The precomputed top‑3 share on Medicare is 98.2%, driven by U0003, U0005, and G2023, which shows the Medicare book of business is almost entirely composed of COVID testing and specimen collection. On Medicaid the concentration is even stronger: the top‑3 codes account for 99.4% of Medicaid revenue, again U0003, U0005, and G2023.
Medicaid billing demonstrates an extraordinary in‑state footprint for COVID testing: U0003 is reported as 2.3M claims and $98.4M revenue and ranks #1 of 127 in‑state (100th percentile; extreme outlier), U0005 is 2.3M claims and $31.8M revenue and ranks #1 of 142 (100th percentile; extreme outlier), and G2023 is 547.6K claims and $8.2M revenue and ranks #1 of 179 (100th percentile; extreme outlier). These three #1 state rankings and the “extreme outlier” designation indicate the provider is the dominant Medicaid supplier of high‑throughput SARS‑CoV‑2 testing and specimen collection in the state.
Nationally on Medicare the provider shows above‑average placement for the same COVID testing codes but without the statewide dominance seen in Medicaid: U0003 on Medicare is 6K claims and $446.2K revenue and ranks #38 of 973 (96th percentile; typical, unremarkable volume) and U0005 is 6K claims and $150.4K revenue and ranks #45 of 1090 (96th percentile; typical, unremarkable volume). These national ranks place the lab in a high percentile for those codes, suggesting meaningful national presence for COVID testing on Medicare, even if paid amounts are modest compared with its Medicaid footprint.
Service‑line mix beyond COVID testing is present but minor in dollar impact. Routine clinical chemistry and hematology codes (examples: 82306 at $15.8K Medicaid and $2.3K Medicare, 80061 at $15.7K Medicaid and $1.5K Medicare, and 80053 at $4.1K Medicaid and $1.3K Medicare) appear in the top lists but contribute only small proportions of revenue versus the top three COVID codes. Medicaid also shows some definitive drug testing revenue (G0483: 2.1K claims, $388.8K revenue, rank #16 of 32 in‑state), indicating ancillary forensic/toxicology capacity that is meaningful at a secondary level but not a primary revenue driver.
From a business and contract perspective, the provider operates like a high‑throughput COVID diagnostics and specimen‑collection center: the dominant codes (U0003, U0005, G2023) are specialized SARS‑CoV‑2 PCR and collection procedures and the claim counts (e.g., 2.3M claims for U0003 and U0005 on Medicaid) imply mass testing throughput rather than a broad, diversified outpatient lab panel mix. Payers should treat the relationship as concentrated on pandemic testing services when assessing network value, utilization trends, or negotiation leverage.
Operational and financial concentration creates sensitivity to changes in COVID testing demand or reimbursement policy. Given that the top‑3 Medicaid codes represent 99.4% of Medicaid revenue and the top‑3 Medicare codes represent 98.2% of Medicare revenue, any shifts in volume, coding policy, or payment for U0003/U0005/G2023 could materially affect this provider’s revenue stream. Analysts evaluating contracting or capitation exposure should consider contingency plans because routine lab services form only a small share of current revenue.
The provider has a multi‑year presence in the NPI registry (enumerated 2013‑09‑10, ~13 years ago), which supports that this is an established laboratory operation that has scaled COVID testing within an existing organizational tenure rather than a brand‑new entrant established solely for pandemic work. This tenure plus the extreme in‑state rankings on Medicaid suggests an operational ramp and sustained investment in SARS‑CoV‑2 testing capacity.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 6,030 | $70 | $446.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 6,020 | $30 | $150.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 610 | $20 | $14K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 80 | $30 | $2.3K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 100 | $20 | $1.5K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 110 | $10 | $1.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 130 | $10 | $1.3K |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 30 | $40 | $1.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 130 | $10 | $1K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 80 | $10 | $840 |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 86769 | 14 | 20 | 100 | $40 | $140.5K |
| U0003 | 5 | 80 | 110 | $70 | $101.7K |
| 82306 | 101 | 250 | 50 | $30 | $79K |
| 84443 | 191 | 380 | 100 | $20 | $65.5K |
| 80061 | 197 | 370 | 130 | $10 | $65.4K |
| 80053 | 236 | 560 | 90 | $10 | $50.8K |
| U0005 | 7 | 90 | 120 | $20 | $35.3K |
| G2023 | 15 | 40 | 380 | $20 | $33.9K |
| 84439 | 94 | 170 | 90 | $10 | $33.2K |
| 83036 | 189 | 510 | 50 | $10 | $26.6K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
76 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,288,470 | $40 | $98.4M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,269,810 | $10 | $31.8M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 547,600 | $20 | $8.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,060 | $190 | $388.8K |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 6,270 | $30 | $181.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,570 | $50 | $84.8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 310 | $120 | $35.5K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 3,160 | $10 | $15.8K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 5,250 | $1 | $15.7K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 1,170 | $10 | $12.8K |
Showing 1–10 of 76
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
76 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 130 | 3,180 | $60 | $4.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16 | 30 | 2,020 | $110 | $2M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 14 | 40 | 590 | $20 | $1.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 99 | 150 | 3,680 | $30 | $1.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 110 | 110 | 1,810 | $50 | $930.1K |
| 86003 | The lab analyst performs the technical lab test to analyze a specimen such as serum for allergen–specific immunoglobulin E (IgE), using a crude allergen extract. The test result is quantitative or… | 15 | 20 | 930 | $40 | $914.5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 19 | 30 | 1,680 | $80 | $883.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1 | 140 | 5,590 | $20 | $823.1K |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 9 | 60 | 280 | $40 | $728.3K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 45 | 70 | 510 | $10 | $610.7K |
Showing 1–10 of 76
Other providers in the same ZIP code as Infinity Diagnostics Laboratory, Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Marise Mc Neeley | NJ | Anatomic Pathology Physician | $135.6K | $0 |
| Rakesh Singh | NJ | Internal Medicine Physician | $52.8K | $1.9K |
| Costco Wholesale Corporation | NJ | Community/Retail Pharmacy | $36.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.